Contrarian Stock Market Investing News - Featuring Bargain Stocks » Sequenom http://www.contrarianprofits.com Access market-beating ideas from the world's top investment gurus on stock market investing, the gold market, ETFs, Forex trading and real estate values. Mon, 10 May 2010 15:10:45 +0000 http://wordpress.org/?v=2.8.5 en hourly 1 Sequenom Gains 20% on Down’s Syndrome Discovery http://www.contrarianprofits.com/articles/sequenom-gains-20-on-down%e2%80%99s-syndrome-discovery/2843 http://www.contrarianprofits.com/articles/sequenom-gains-20-on-down%e2%80%99s-syndrome-discovery/2843#comments Wed, 04 Jun 2008 20:52:39 +0000 J. Christoph Amberger http://www.contrarianprofits.com/articles/sequenom-gains-20-on-down%e2%80%99s-syndrome-discovery/2843 Shares of biotech smallcap Sequenom, Inc. (Nasdaq:SQNM) soared over 20% in morning trading after the genetics and molecular diagnostic company reported that its nucleic acid technology is able to detect Down’s syndrome in pregnant women.

Sequenom, Inc. is a San Diego-based genetics and molecular diagnostic company that provides genetic analysis products/services and develops diagnostic tests initially targeted at non-invasive prenatal genetic disorders.

The stock currently trades just below $10, up over 100% from its March 2008 low of $4.25, but still comfortably below its 52-week high of $11.63.

Momentum traders should buy this stock in view of the media dissemination chain of positive news, which should keep the company in the news for at least until the weekend. Buy at current levels below…

]]> Shares of biotech smallcap Sequenom, Inc. (Nasdaq:SQNM) soared over 20% in morning trading after the genetics and molecular diagnostic company reported that its nucleic acid technology is able to detect Down’s syndrome in pregnant women.

Sequenom, Inc. is a San Diego-based genetics and molecular diagnostic company that provides genetic analysis products/services and develops diagnostic tests initially targeted at non-invasive prenatal genetic disorders.

The stock currently trades just below $10, up over 100% from its March 2008 low of $4.25, but still comfortably below its 52-week high of $11.63.

Momentum traders should buy this stock in view of the media dissemination chain of positive news, which should keep the company in the news for at least until the weekend. Buy at current levels below $9.50, with a 20-25% profit short-to-medium-term profit target.

Source: Sequenom Gains 20% on Down’s Syndrome Discovery

]]> http://www.contrarianprofits.com/articles/sequenom-gains-20-on-down%e2%80%99s-syndrome-discovery/2843/feed 0